A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Patients were treated with lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity. Among 37 evaluable patients, the median age was 74 years (range, 60-94), 21 (57%) were female, 19 (51%) had prior myelodysplastic syndrome, and 30 (81%) had pretreatment cytogenetic studies evaluated centrally. Six had isolated del(5q), 1 had del(5q) and +8, 23 had complex cytogenetics, and 7 others had del(5q) identified locally. Fourteen patients (38%) completed induction therapy: 7 patients died during induction therapy, 8 had disease progression, 7 had nonfatal adverse events, and 1 entered hospice. Eight patients started maintenance therapy. Five patients (14%) achieved a partial or complete response, 2 with isolated del(5q) and 3 with complex cytogenetics. Relapse-free survival was 5 months (range, 0-19). Median overall survival was 2 months for the entire population. In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365.

[1]  A. Jankowska,et al.  Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide , 2012, Journal of Hematology & Oncology.

[2]  R. Vij,et al.  A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia , 2011 .

[3]  J. Maciejewski,et al.  Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes , 2011, American journal of hematology.

[4]  M. Grever,et al.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. O'keefe,et al.  Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q) , 2010 .

[6]  H. Dombret,et al.  Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM) , 2010 .

[7]  K. Götze,et al.  A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial , 2010 .

[8]  J. Gamble,et al.  Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells. , 2010, Blood.

[9]  Клинические дисциплины.  Cancer and Leukemia Group B , 2010 .

[10]  J. Burger.  Angiopoietin-2 in CLL. , 2010, Blood.

[11]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Petersen,et al.  CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT , 2010, Bone Marrow Transplantation.

[13]  J. Issa,et al.  Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.

[14]  J. Byrd,et al.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.

[15]  A. Stamatoullas,et al.  Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. , 2009, Blood.

[16]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[17]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[18]  A. Advani,et al.  Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia , 2007, Cancer.

[19]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[20]  J. Lancet,et al.  Treatment of deletion 5q acute myeloid leukemia with lenalidomide , 2007, Leukemia.

[21]  D. Steensma,et al.  Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome , 2006, Leukemia.

[22]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[23]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[24]  C. Earle,et al.  Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly , 2005, Drugs & aging.

[25]  R. Stone,et al.  Acute myeloid leukemia. , 2012, Hematology. American Society of Hematology. Education Program.

[26]  D. Neuberg,et al.  A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.

[27]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[29]  M. Fridkin,et al.  Adhesion of human platelets to serum amyloid A. , 2002, Blood.

[30]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[31]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[32]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[33]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[34]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[35]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[36]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .